JP2020500163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500163A5 JP2020500163A5 JP2019521018A JP2019521018A JP2020500163A5 JP 2020500163 A5 JP2020500163 A5 JP 2020500163A5 JP 2019521018 A JP2019521018 A JP 2019521018A JP 2019521018 A JP2019521018 A JP 2019521018A JP 2020500163 A5 JP2020500163 A5 JP 2020500163A5
- Authority
- JP
- Japan
- Prior art keywords
- ala
- controlled release
- gly
- preparation
- release preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003405 delayed action preparation Substances 0.000 claims 43
- 230000000324 neuroprotective effect Effects 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 38
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 18
- 238000002360 preparation method Methods 0.000 claims 14
- 238000013268 sustained release Methods 0.000 claims 13
- 239000012730 sustained-release form Substances 0.000 claims 13
- 210000003169 central nervous system Anatomy 0.000 claims 11
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 claims 10
- 238000013270 controlled release Methods 0.000 claims 9
- 108010079364 N-glycylalanine Proteins 0.000 claims 8
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 8
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims 6
- AHLFJIALFLSDAQ-UHFFFAOYSA-N 2-(pentylazaniumyl)acetate Chemical compound CCCCCNCC(O)=O AHLFJIALFLSDAQ-UHFFFAOYSA-N 0.000 claims 6
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 6
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 6
- 229920002988 biodegradable polymer Polymers 0.000 claims 5
- 239000004621 biodegradable polymer Substances 0.000 claims 5
- 108010011459 Exenatide Proteins 0.000 claims 4
- 230000008499 blood brain barrier function Effects 0.000 claims 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims 4
- 229960001519 exenatide Drugs 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 239000011247 coating layer Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- 230000003204 osmotic effect Effects 0.000 claims 2
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- QJMCHPGWFZZRID-BQBZGAKWSA-N Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O QJMCHPGWFZZRID-BQBZGAKWSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- JPNRPAJITHRXRH-BQBZGAKWSA-N Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O JPNRPAJITHRXRH-BQBZGAKWSA-N 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims 1
- 208000020339 Spinal injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000025698 brain inflammatory disease Diseases 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 claims 1
- 230000002572 peristaltic effect Effects 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023016292A JP2023065401A (ja) | 2016-10-20 | 2023-02-06 | 中枢神経系に神経保護ポリペプチドを送達する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410748P | 2016-10-20 | 2016-10-20 | |
| US62/410,748 | 2016-10-20 | ||
| PCT/US2017/057606 WO2018075901A1 (en) | 2016-10-20 | 2017-10-20 | Methods of delivering a neuroprotective polypeptide to the central nervous system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016292A Division JP2023065401A (ja) | 2016-10-20 | 2023-02-06 | 中枢神経系に神経保護ポリペプチドを送達する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020500163A JP2020500163A (ja) | 2020-01-09 |
| JP2020500163A5 true JP2020500163A5 (enExample) | 2020-11-26 |
| JPWO2018075901A5 JPWO2018075901A5 (enExample) | 2024-11-28 |
| JP7626362B2 JP7626362B2 (ja) | 2025-02-07 |
Family
ID=60382598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521018A Active JP7626362B2 (ja) | 2016-10-20 | 2017-10-20 | 中枢神経系に神経保護ポリペプチドを送達する方法 |
| JP2023016292A Pending JP2023065401A (ja) | 2016-10-20 | 2023-02-06 | 中枢神経系に神経保護ポリペプチドを送達する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016292A Pending JP2023065401A (ja) | 2016-10-20 | 2023-02-06 | 中枢神経系に神経保護ポリペプチドを送達する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273130B2 (enExample) |
| EP (2) | EP3528836A1 (enExample) |
| JP (2) | JP7626362B2 (enExample) |
| KR (2) | KR102687778B1 (enExample) |
| CN (1) | CN110191717A (enExample) |
| AU (1) | AU2017345724B2 (enExample) |
| BR (1) | BR112019008021A2 (enExample) |
| CA (1) | CA3040906A1 (enExample) |
| MX (1) | MX2019004476A (enExample) |
| SG (1) | SG11201903462UA (enExample) |
| WO (1) | WO2018075901A1 (enExample) |
| ZA (1) | ZA201902486B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201903462UA (en) | 2016-10-20 | 2019-05-30 | Peptron Inc | Methods of delivering a neuroprotective polypeptide to the central nervous system |
| EP4005587A4 (en) * | 2019-07-29 | 2023-08-09 | Peptron, Inc. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA OR SUPPRESSION OF THEIR PROGRESSION |
| BR112022001595A2 (pt) * | 2019-07-29 | 2022-03-22 | Peptron Inc | Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa |
| US20230190657A1 (en) * | 2020-05-22 | 2023-06-22 | Trustees Of Boston University | Methods and compositions for treating a fibrotic disease |
| CN112014193B (zh) * | 2020-07-24 | 2021-06-15 | 武汉大学中南医院 | 一种新的fj染色方法和装置 |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| CN116392576A (zh) * | 2023-05-26 | 2023-07-07 | 南通大学 | 一种gip受体激动剂在制备治疗脊髓损伤修复靶点药物中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
| US6261584B1 (en) | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| PL189289B1 (pl) | 1996-02-02 | 2005-07-29 | Alza Corp | Sposób przygotowania implantowanego układu do dostarczania substancji aktywnej |
| US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
| US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| ZA981610B (en) | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
| MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| CA2299425A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| PT1032587E (pt) | 1997-11-14 | 2008-04-21 | Amylin Pharmaceuticals Inc | Novos compostos agonistas de exendina |
| KR100576583B1 (ko) | 1997-12-22 | 2006-05-04 | 알자 코포레이션 | 서방성 약물 송달 장치용 속도 조절막 |
| WO1999033446A1 (en) | 1997-12-29 | 1999-07-08 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
| KR100568917B1 (ko) | 1997-12-30 | 2006-04-07 | 알자 코포레이션 | 멤브레인 플러그를 갖는 익제 전달장치 |
| CA2356860C (en) | 1998-12-31 | 2006-11-07 | Alza Corporation | Osmotic delivery system having space efficient piston |
| EP1328256B1 (en) | 1999-12-21 | 2005-10-19 | Alza Corporation | Valve for osmotic devices |
| US7163688B2 (en) | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| CN100453130C (zh) | 2002-06-26 | 2009-01-21 | 精达制药公司 | 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞 |
| US7014636B2 (en) | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
| EP1613389B8 (en) | 2003-03-31 | 2008-05-07 | Intarcia Therapeutics, Inc. | Osmotic pump with means for dissipating internal pressure |
| US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US20050175701A1 (en) | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
| US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
| US8168222B2 (en) * | 2004-09-07 | 2012-05-01 | Board Of Regents Of The University Of Nebraska | Amphiphilic polymer-protein conjugates and methods of use thereof |
| MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
| MX2009001114A (es) | 2006-08-09 | 2009-02-10 | Intarcia Therapeutics Inc | Sistemas de suministro osmotico y ensambles de piston. |
| KR100805208B1 (ko) | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
| CN104000779A (zh) | 2007-04-23 | 2014-08-27 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| DK2462246T3 (da) | 2009-09-28 | 2017-11-06 | Intarcia Therapeutics Inc | Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse |
| US9259432B1 (en) * | 2011-01-31 | 2016-02-16 | Parminder J. S. Vig | Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases |
| EP2723359A4 (en) * | 2011-06-24 | 2015-03-11 | Amylin Pharmaceuticals Llc | METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS |
| JP6226510B2 (ja) | 2012-01-27 | 2017-11-08 | キヤノン株式会社 | 画像処理システム、処理方法及びプログラム |
| ITMI20130325A1 (it) | 2013-03-05 | 2014-09-06 | Telecom Italia Spa | Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente |
| JP2015192425A (ja) | 2014-03-28 | 2015-11-02 | 富士通株式会社 | デマンド収容変更順序決定方法、およびデマンド収容変更順序決定プログラム |
| US20170035856A1 (en) | 2014-04-16 | 2017-02-09 | Shandong Luye Pharmaceutical Co., Ltd. | Exenatide-containing composition and preparation method therefor |
| SG11201903462UA (en) | 2016-10-20 | 2019-05-30 | Peptron Inc | Methods of delivering a neuroprotective polypeptide to the central nervous system |
-
2017
- 2017-10-20 SG SG11201903462UA patent/SG11201903462UA/en unknown
- 2017-10-20 KR KR1020217022385A patent/KR102687778B1/ko active Active
- 2017-10-20 AU AU2017345724A patent/AU2017345724B2/en active Active
- 2017-10-20 WO PCT/US2017/057606 patent/WO2018075901A1/en not_active Ceased
- 2017-10-20 US US16/342,685 patent/US11273130B2/en active Active
- 2017-10-20 JP JP2019521018A patent/JP7626362B2/ja active Active
- 2017-10-20 MX MX2019004476A patent/MX2019004476A/es unknown
- 2017-10-20 KR KR1020197014421A patent/KR20190086460A/ko not_active Ceased
- 2017-10-20 BR BR112019008021A patent/BR112019008021A2/pt unknown
- 2017-10-20 CA CA3040906A patent/CA3040906A1/en active Pending
- 2017-10-20 CN CN201780078697.6A patent/CN110191717A/zh active Pending
- 2017-10-20 EP EP17800650.8A patent/EP3528836A1/en not_active Withdrawn
- 2017-10-20 EP EP25181393.7A patent/EP4635569A2/en active Pending
-
2019
- 2019-04-17 ZA ZA2019/02486A patent/ZA201902486B/en unknown
-
2021
- 2021-11-09 US US17/522,687 patent/US11771657B2/en active Active
-
2023
- 2023-02-06 JP JP2023016292A patent/JP2023065401A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500163A5 (enExample) | ||
| EP2134329B1 (en) | Composition and microsphere for controlled-release of exendin, and method of preparing the same | |
| ES2552646T3 (es) | Exendinas para disminuir el colesterol y los triglicéridos | |
| Lacroix et al. | The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations | |
| CA2320371A1 (en) | Inotropic and diuretic effects of exendin and glp-1 | |
| AU754707B2 (en) | Method for administering monomeric insulin analogs | |
| JP7626362B2 (ja) | 中枢神経系に神経保護ポリペプチドを送達する方法 | |
| CN101588789B (zh) | 用于治疗牛和其它动物炎症的药物组合物和方法 | |
| WO2000047203A1 (en) | Formulation and system for intra-oral delivery of pharmaceutical agents | |
| MX2008016254A (es) | Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia. | |
| CN103732215B (zh) | 组合肽纳米颗粒及掺入其的递送系统 | |
| US20120301535A1 (en) | Combination peptide-nanoparticles and delivery systems incorporating same | |
| US20130137670A1 (en) | Zwitterion solution for low-volume therapeutic delivery | |
| Minchin et al. | Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs | |
| WO2019193417A1 (en) | Composition and method of reducing joint pain associated with hemarthrosis | |
| CN107661288A (zh) | 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备 | |
| Banerjee et al. | A novel peptide nanomedicine for treatment of pancreatogenic diabetes | |
| CN110623944A (zh) | 一种胰高血糖素样肽-1类似物缓释微球制剂及其制备方法 | |
| US9161910B2 (en) | Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type II diabetes | |
| Himori et al. | Assessment of the selectivity of OPC-2009, a new β2-adrenoceptor stimulant, by the use of the blood-perfused trachea in situ and of the isolated blood-perfused papillary muscle of the dog | |
| US20050004221A1 (en) | Intrathecal gabapentin compositions | |
| WO2022046976A1 (en) | An epinephrine injection formulation with very low epinephrine concentration and low impurities during its shelf-life | |
| US20240108573A1 (en) | Nanolipid carrier based formulation for brain delivery through intranasal route and its preparation process | |
| Adams et al. | Drug delivery systems for the treatment of diabetes mellitus: state of the art | |
| JP7518149B2 (ja) | 高濃度インスリン製剤 |